Infectious Disease Clinics of North America volume 23, issue 4, P965-982 2009 DOI: 10.1016/j.idc.2009.06.010 View full text
|
|
Share
Michael D. Nailor, Jack D. Sobel

Abstract: An overview of the mechanism of action, dosing, clinical indications, and toxicities of the glycopeptide vancomycin is provided. The emerging gram-positive bacterial resistance to antimicrobials and its mechanisms are reviewed. Strategies to control this emergence of resistance are expected to be proposed. Newer antimicrobial agents that have activity against vancomycin-resistant organisms are now available and play a critical role in the treatment of life-threatening infections.